Identification of HLA-A0201- and A2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer - PubMed (original) (raw)
Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer
Sadaaki Yamazoe et al. Pancreas. 2011 Aug.
Abstract
Objectives: Mucin 5AC (MUC5AC) was previously identified as being expressed in most pancreatic ductal adenocarcinomas. We studied the significance of MUC5AC expression for the development of pancreatic ductal adenocarcinoma and the possibility of using MUC5AC as a target for immunotherapy for pancreatic cancer.
Methods: We immunohistochemicaly tested MUC5AC expression in 134 specimens. To assess the possibility of using the MUC5AC protein to develop an anticancer vaccine, we examined MUC5AC for possible peptide epitopes to elicit cytotoxic T lymphocytes (CTLs).
Results: In immunohistochemical analysis, MUC5AC was absent from all cell types of the normal pancreas but was expressed de novo in 79% of invasive ductal adenocarcinoma. Clinicopathologically, primary tumors with lymph node metastasis had a significantly higher expression of MUC5AC. Next, we successfully established CTL clones stimulated by the MUC5AC-A02-1398 (FLNDAGACV) and MUC5AC-A24-716 (TCQPTCRSL) peptides, which have specific cytotoxicity against the corresponding HLA-A*0201- and A*2402-positive target cells pulsed with the candidate peptide. Each CTL clone also demonstrated its cytotoxic activity toward pancreatic cancer cells endogenously expressing MUC5AC.
Conclusions: Our results suggest that MUC5AC is a novel tumor-associated antigen that has potential application as a vaccine against pancreatic cancer.
Similar articles
- Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence.
Manne A, Kasi A, Esnakula AK, Paluri RK. Manne A, et al. Int J Mol Sci. 2023 Apr 30;24(9):8087. doi: 10.3390/ijms24098087. Int J Mol Sci. 2023. PMID: 37175794 Free PMC article. Review. - Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Imai K, et al. Clin Cancer Res. 2008 Oct 15;14(20):6487-95. doi: 10.1158/1078-0432.CCR-08-1086. Clin Cancer Res. 2008. PMID: 18927288 - The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ. Peiper M, et al. Eur J Immunol. 1997 May;27(5):1115-23. doi: 10.1002/eji.1830270511. Eur J Immunol. 1997. PMID: 9174600 - Identification of HLA-A*2402-restricted epitope peptide derived from ERas oncogene expressed in human scirrhous gastric cancer.
Iwauchi T, Tanaka H, Yamazoe S, Yashiro M, Yoshii M, Kubo N, Muguruma K, Sawada T, Ohira M, Hirakawa K. Iwauchi T, et al. Cancer Sci. 2011 Apr;102(4):683-9. doi: 10.1111/j.1349-7006.2010.01843.x. Epub 2011 Feb 8. Cancer Sci. 2011. PMID: 21205089 - The immune network in pancreatic cancer development and progression.
Wörmann SM, Diakopoulos KN, Lesina M, Algül H. Wörmann SM, et al. Oncogene. 2014 Jun 5;33(23):2956-67. doi: 10.1038/onc.2013.257. Epub 2013 Jul 15. Oncogene. 2014. PMID: 23851493 Review.
Cited by
- Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes.
Manne A, Esnakula A, Sheel A, Sara A, Manne U, Paluri RK, He K, Yang W, Sohal D, Kasi A, Noonan AM, Mittra A, Hays J, Roychowdhury S, Malalur P, Rahman S, Jin N, Cloyd JM, Tsai S, Ejaz A, Pitter K, Miller E, Thanikachalam K, Dillhoff M, Yu L. Manne A, et al. Int J Mol Sci. 2024 Aug 20;25(16):9041. doi: 10.3390/ijms25169041. Int J Mol Sci. 2024. PMID: 39201728 Free PMC article. - Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence.
Manne A, Kasi A, Esnakula AK, Paluri RK. Manne A, et al. Int J Mol Sci. 2023 Apr 30;24(9):8087. doi: 10.3390/ijms24098087. Int J Mol Sci. 2023. PMID: 37175794 Free PMC article. Review. - Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.
Alarcon NO, Jaramillo M, Mansour HM, Sun B. Alarcon NO, et al. Pharmaceutics. 2022 Jul 11;14(7):1448. doi: 10.3390/pharmaceutics14071448. Pharmaceutics. 2022. PMID: 35890342 Free PMC article. Review. - Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma.
Dwertmann Rico S, Büscheck F, Dum D, Luebke AM, Kluth M, Hube-Magg C, Hinsch A, Höflmayer D, Perez D, Izbicki JR, Neipp M, Mofid H, Daniels T, Isbert C, Fraune C, Möller K, Menz A, Bernreuther C, Lebok P, Clauditz T, Sauter G, Uhlig R, Wilczak W, Simon R, Steurer S, Burandt E, Marx A, Krech T. Dwertmann Rico S, et al. Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221106504. doi: 10.1177/03946320221106504. Int J Immunopathol Pharmacol. 2022. PMID: 35764407 Free PMC article. - Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma.
Manne A, Esnakula A, Abushahin L, Tsung A. Manne A, et al. Cancers (Basel). 2021 Jun 19;13(12):3059. doi: 10.3390/cancers13123059. Cancers (Basel). 2021. PMID: 34205412 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials